Eli Lilly announced at the beginning of March ... including pre-filled insulin pens and vials. The company suggested that this would mean patients would pay $25-35 for their insulin.

Eli Lilly’s big-selling insulin, Humalog, faces cut-price competition ... which is available in vial form or as a disposable pen. Sanofi fights back This represents Sanofi's first foray into ...

Novo Nordisk’s semaglutide diabetes and weight loss drugs, Ozempic and Wegovy, are no longer officially in shortage in the US ...

How weight loss drugs actually work, and how big-name prescriptions differ from each other. What investors need to know about ...

March 10, 2025 Eli ... over insulin South Africa's competition watchdog is investigating drugmakers Novo Nordisk and Sanofi over possible anti-competitive practices in the human insulin pen ...

The exact price depends on dosage, pharmacy, location, insurance coverage, and available savings programs. Fully ...

Eli Lilly (NYSE: LLY) stock has had plenty of good trading sessions over the past year or so, but Monday's sure wasn't among them. The storied pharmaceutical company's shares lost nearly 5% of ...

Like many pharma stocks, Eli Lilly (NYSE: LLY) offers investors a bit of safety -- and it's an element you can count on during any economic environment. This is because patients need their ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE ... Its key products include insulin therapies, GLP-1 receptor agonists for diabetes and obesity, cancer ...

1,2 The Egyptian Drug Authority approved the insulin glargine injection manufactured by EVA Pharma through a collaboration with Eli Lilly and Company (NYSE: LLY). Launched in 2022, the ...